NR1H4 and metabolic dysfunction-associated steatohepatitis: Several lines of evidence have supported that hepatic FXR activation can potentially attenuate steatohepatitis based on the beneficial outcomes observed in patients with NASH treated with FXR agonists [40,41,42], whereas intestinal FXR activation has been reported to promote NAFLD pathology [43].